How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily

Google News1/22/2026

Summary

Johnson & Johnson (J&J) reported its fourth-quarter and full-year 2025 earnings, highlighting a strategy focused on leading in the cancer fight, with oncology sales exceeding $25 billion. J&J's MedTech sales increased by 7.5% in Q4. Despite facing challenges such as tariffs and a pricing deal from Trump, J&J anticipates 2026 profits to surpass Wall Street estimates.

Share:XRedditLinkedIn

Advertisement

Lindy Score Breakdown (V4.2)

85d
Age
1
Sources
from cluster
2016
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^2016/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^2016/48 = 0.000000) reduced it below 0.5

Score BreakdownRisk 50

Source Reputation: Low-trust source (6/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 84 days - proven survivor

Stories gain Lindy status through source reputation, network consensus, and time survival.

Breaking Similar stories

Anti-Lindy Similar stories